Korean maker of aesthetic medical devices (HIFU/RF skin-tightening systems) sold to dermatology and plastic-surgery clinics worldwide.
Korean maker of aesthetic medical devices (HIFU/RF skin-tightening systems) sold to dermatology and plastic-surgery clinics worldwide.
Sells its machines to clinics largely through distributors, and earns repeat income from the single-use cartridges each treatment uses up, so a machine already installed keeps generating orders. Exports are a large part of sales.
Moat: narrow (IP / patents, regulatory licence). Patented energy-based device technology plus regulatory clearances across many export markets.
Headquarters: Seoul, South Korea · Founded: 2007 · Employees: 528
Size CLASSYS (214150.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $1.08B, the 229th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩22,200 on 18 Nov 2026.
Performance Over six months the shares fell 59.6%, against -4.5% for the median peer and -37.2% for the South Korea market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 16.2% over the last twelve months (peer median +8.3%); the operating margin is 43.2% (peer median 11.6%).
Valuation It trades at 13.7× forward earnings against a peer median of 18.5× (3rd cheapest of 12).
Price implies For today's price to make sense, revenue must grow about -9% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -44 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 13.9 points above its cost of capital (5.9% WACC).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩369B | ₩337B | ₩243B | ₩180B | ₩142B |
| Revenue growth | — | +39% | +35% | +27% | — |
| Gross profit | ₩263B | ₩250B | ₩187B | ₩139B | ₩107B |
| EBITDA | ₩175B | ₩185B | ₩130B | ₩93.9B | ₩72.3B |
| Net income | ₩111B | ₩132B | ₩97.9B | ₩74.2B | ₩75.4B |
| Free cash flow | ₩39.3B | ₩101B | ₩98.7B | ₩60.2B | ₩27.3B |
| Capital expenditure | ₩36.4B | ₩19.3B | ₩10.8B | ₩6.11B | ₩28.0B |
| Total debt | ₩141B | ₩86.8B | ₩91.1B | ₩65.6B | ₩67.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| CLASSYS 214150.KS | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% |
| Hugel 145020.KS | $1.69B | -30% | +17% | 38% | 18.1× | -12.1% |
| Lunit 328130.KS | $883M | -15% | +23% | -63% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 214150.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -25.4% | -5.1% | 3rd lowest of 21 |
| 6-month return | -59.6% | -4.5% | lowest of 20 |
| Distance from 52-week high | -71.4% | -29.4% | lowest of 21 |
| Revenue growth (TTM) | +16.2% | +8.3% | 4th highest of 19 |
| Operating margin | 43.2% | 11.6% | highest of 20 |
| Forward P/E | 13.7× | 18.5× | 3rd cheapest of 12 |
| Growth the price implies (Req g, 7 yrs) | -9.2% | 8.2% | least demanding of 13 |
| Growth delivered (Del g) | +34.5% | +9.3% | 2nd highest of 13 |
| Hurdle (Req g minus delivered) | -43.7 pp | -1.1 pp | least demanding of 13 |
| ROIC minus cost of capital | +13.9 pp | +0.3 pp | 6th highest of 19 |
| EV / EBITDA | 8.4× | 10.3× | 3rd cheapest of 7 |
| Net debt / EBITDA | 0.2× | 1.2× | 4th least indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CLASSYS 214150.KS | South Korea | $1.08B | -60% | +16% | 43% | 13.7× | -9.2% | +34.5% |
| Integra LifeSciences IART | United States | $1.08B | -10% | +1% | 12% | 6.0× | 5.9% | +3.6% |
| Freenome FRNM | United States | $1.08B | n/a | n/a | 36% | n/a | n/a | n/a |
| Mingyue Optical Lens 301101.SZ | China | $1.07B | -4% | +14% | 25% | 31.6× | 8.8% | +8.8% |
| Alphatec ATEC | United States | $1.10B | -14% | +15% | -3% | 15.1× | n/a | n/a |
| Guangzhou Hexin Instrument 688622.SS | China | $1.06B | +21% | -29% | -74% | n/a | n/a | n/a |
| SI-BONE SIBN | United States | $1.06B | +59% | +14% | -8% | n/a | n/a | n/a |
| IRadimed IRMD | United States | $1.05B | -9% | +11% | 32% | 34.3× | 18.5% | +21.5% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 18.2× | 1.7% | +9.9% |
| Castle Biosciences CSTL | United States | $1.03B | +67% | +10% | -7% | n/a | 57.7% | +40.6% |
| Eckert & Ziegler EUZ.DE | Germany | $1.03B | -2% | +4% | 26% | 18.5× | 7.7% | +12.1% |
| Beijing Wandong Medical Technology 600055.SS | China | $1.03B | -26% | -11% | -33% | n/a | n/a | n/a |
| Inno Laser Technology 301021.SZ | China | $1.03B | -33% | +17% | 9% | n/a | 50.8% | +8.6% |
| PHC 6523.T | Japan | $1.02B | +34% | +3% | 8% | 7.5× | -4.0% | +3.5% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 24.9× | 11.3% | -3.5% |
| Amoy Diagnostics 300685.SZ | China | $1.01B | -15% | +7% | 34% | 19.3× | 4.9% | +10.4% |
| Edan Instruments 300206.SZ | China | $1.00B | -19% | +14% | 17% | 18.0× | 6.9% | -2.9% |
| Ceribell CBLL | United States | $995M | +42% | +31% | -70% | n/a | n/a | n/a |
| INKON Life Technology 300143.SZ | China | $985M | -23% | +22% | 12% | 50.3× | 10.7% | +12.9% |
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -2% | n/a | n/a | n/a |